Effects of Kinesio Taping Application in Women With Overactive Bladder

Overview

The aim of this study is to compare the effects of kinesio tape application on bladder symptoms and quality of life in women with overactive bladder (OAB).

Full Title of Study: “Assistant Professor, Physioterapist, PhD”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Factorial Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: June 2019

Interventions

  • Other: Kinesio tape application
    • Kinesio tape application combined with pelvic floor exercises will be performed.Taping is carried out for 2 days/week in 6 weeks. The exercise program is performed every day for 6 weeks
  • Other: Sham tape application
    • Sham tape application combined with pelvic floor exercises will be performed.Sham taping is carried out for 2 days/week in 6 weeks. The exercise program is performed every day for 6 weeks

Arms, Groups and Cohorts

  • Experimental: Kinesio tape group
    • Kinesio tape application and pelvic floor exercise have been applied
  • Sham Comparator: Control group
    • Sham kinesio tape application and pelvic floor exercise have been applied

Clinical Trial Outcome Measures

Primary Measures

  • The severity of overactive bladder symptoms assessed with Overactive Bladder Questionnaire_V8
    • Time Frame: Change from baseline bladder symptoms at 6 weeks
    • Overactive Bladder Questionnaire_V8 assessing severity of overactive bladder symptoms will be used. This scale includes items on urgency, incontinence, nocturia and voiding frequency, as defined by the International Continence Society, referring to the previous four weeks. Overactive Bladder Questionnaire_V8 assessing severity of overactive bladder symptoms will be used. This scale includes items on urgency, incontinence, nocturia and voiding frequency, as defined by the International Continence Society. The final score is the sum of the partial scores obtained for each of the eight questions, ranging from 0 to 40.

Secondary Measures

  • Urgency complaint assessed with the Perception of Intensity of Urgency Scale
    • Time Frame: Change from baseline urgency complaints at 6 weeks
    • The patient’s Perception of Intensity of Urgency Scale assessing urgency complaints will be used. This scale is scored on 0 and 4 points (the best score is ‘0’ and the worst score is ‘4’) based on urgency complaints. Higher scores indicate more severe urgency complaints.
  • Daily urinary frequency measured with voiding diary
    • Time Frame: Change from baseline the average daily urinary frequency at 6 weeks
    • Patients will be also instructed to keep voiding diary for three days. In this diary, the average daily urinary frequency will be recorded.
  • The number of nocturia measured with voiding diary
    • Time Frame: Change from baseline the average number of nocturia at 6 weeks
    • Patients will be also instructed to keep voiding diary for three days. In this diary, the average number of nocturia will be recorded.
  • The number of urinary incontinence measured with voiding diary
    • Time Frame: Change from baseline the average number of urinary incontinence at 6 weeks
    • Patients will be also instructed to keep voiding diary for three days. In this diary, the average number of urinary incontinence will be recorded.
  • pelvic floor muscle strength measured with Modified Oxford Grading scale
    • Time Frame: Change from baseline pelvic floor muscle strength at 6 weeks
    • The modified Oxford Grading Scale quantifies pelvic floor muscle strength as: 0, no contraction; 1, flicker; 2, weak; 3, moderate; 4, good; and 5, strong.
  • quality of life assessed with King’s Health Questionnaire (KHQ)
    • Time Frame: Change from baseline quality of life at 6 weeks
    • King’s Health Questionnaire assessing quality of life related to urinary problems will be used. This questionnaire consists of two parts and 32 items. The first part (21 items) contains two single-item questions that address General Health Perception and Incontinence Impact and the following seven multi-item domains: Role, Physical, and Social Limitations, Limitations in Personal Relationship, Emotional Problems, Sleep and Energy Disturbances associated with UI, and Severity Measures for UI. The second part has an 11-item Symptom Severity Scale (SSS) that assesses the presence and severity of urinary symptoms. While the entire SSS is scored from 0 (best) to 30 (worst), the minimum possible score is 0 (best health) and the maximum possible score is 100 (worst health) for all other KHQ domains.

Participating in This Clinical Trial

Inclusion Criteria

  • 20 to 65 years of age, – having overactive bladder – being volunteer Exclusion Criteria:

  • pregnancy, – only stress incontinence, – the presence of a malignant condition with a history of acute infection, – having a mental problem to prevent co-morbidity, evaluation and cooperative

Gender Eligibility: Female

Minimum Age: 20 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Ataturk Training and Research Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Seyda TOPRAK CELENAY, Assistant Professor – Ataturk Training and Research Hospital
  • Overall Official(s)
    • Seyda TOPRAK CELENAY, Principal Investigator, Ankara Yildirim Beyazıt University
    • Zehra Korkut, Study Chair, KTO Karatay University
    • Kemal Oskay, Study Chair, Ankara Gazi Mustafa Kemal Hospital
  • Overall Contact(s)
    • Seyda TOPRAK CELENAY, +90-534-041-3986, sydtoprak@hotmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.